Clinical-stage CEO

Persona 01 / 04

— A scene from clinical operations

The clinical-stage CEO with one or two assets in the clinic.

Series-A or B, twelve to forty people, one or two programs that matter. The CEO is the one who reads the FDA letter first and the one who has to call the board. Most of what they need is not in any single database — it lives across registries, dockets, IP filings, and earnings calls, and it changes weekly.

“

Will my IND get a CRL? What's the regulatory path of least resistance — and who's beating me to the indication?

— a question we hear, in some form, almost every week

What Brioche delivers

A standing intelligence layer for one program. Continuous monitoring of the regulatory perimeter, the competitive set, and the IP space — surfaced as briefings when something material moves, not as dashboards that go unread.

Regulatory perimeter Tracking of every FDA action, advisory committee, and CRL pattern in the indication. New guidance read against your protocol the day it drops.
Competitive moves Comparator trial enrollments, readout timing, sponsor-disclosed endpoints, label-shaping decisions — pulled from registries and 10-Ks, attributed and dated.
IP space New filings against your composition-of-matter and method-of-use claims. Examiner office actions on adjacent applications. Freedom-to-operate degradation flagged early.
Cadence A short briefing each week. A long-form synthesis each month. Direct access between briefings — the question, not the brief.

Illustrative scenario · not a real engagement Scenario sketch

A clinical-stage company developing an oral small-molecule for refractory immune thrombocytopenia (ITP), heading into a Type B meeting.

The CEO has internal certainty about efficacy and external uncertainty about everything else: which endpoints FDA will accept, what the competitive set's enrollment posture says about expected approval timing, and whether a recent patent filing from a comparator sponsor narrows the room to operate.

— Track 01

Precedent. Pull every refractory-ITP regulatory action since the fostamatinib approval. Decompose endpoints, durable response definitions, and FDA's stated rationale for any CRLs in the second-line setting.

— Track 02

Comparators. Map the active competitive set on ClinicalTrials.gov against publicly disclosed timelines, expected primary completions, and sponsor commentary from earnings calls.

— Track 03

IP perimeter. Monitor USPTO and EPO filings adjacent to the asset's chemical class. Flag claim language that would constrain dosing strategy or formulation latitude.

The clinical-stage CEO with one or two assets in the clinic.

What Brioche delivers

A clinical-stage company developing an oral small-molecule for refractory immune thrombocytopenia (ITP), heading into a Type B meeting.

How other teams use Brioche.